Trillium Therapeutics Inc (TRIL.CA) Stock News
TSX:TRIL - Toronto Stock Exchange -
TRIL.CA Latest News, Press Relases and Analysis
Trillium Therapeutics Receives Final Court Order Approving Arrangement
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...
Mentions: TRIL
Trillium Securityholders Approve Acquisition by Pfizer
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...
Mentions: TRIL
Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion
Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc. it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.
Mentions: PFE
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company devel...
Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company dev...
An Aging Population is Increasing the Need for Novel Treatments
FN Media Group Presents Microsmallcap.com Market Commentary
Red-Hot Biotechs to Take Center Stage at Blood Disorder Meeting
High-flying drug developers that have surged in the face of the ongoing coronavirus pandemic will be in focus starting this weekend at the year’s last big medical meeting, putting surging stocks under the microscope for investors who have cheered massive gains.
Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results
CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage ...
Mentions: PFE
Cancer Drug Bet Pays Off for Biotech CEO With 3,600% Stock Surge
When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards.
Gold’s Rise Drives Canada Stock Benchmark in a New Direction
Gold’s strong run is taking Canada’s equity benchmark back to its mining roots.
Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results
TTI-621 study has progressed to the 2.0 mg/kg dosing levelTTI-622 showing early evidence of monotherapy activity$130.8 million of cash and investm...